Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Neuropharmacology. 2012 Jul 15;64:348–356. doi: 10.1016/j.neuropharm.2012.07.016

Fig. 6.

Fig. 6

The effects of a 5-HT1A receptor agonist on PPI in WT and DAT KO mice. PPI in WT and DAT KO mice after administration of saline–saline (sal–sal), saline and 0.3 mg/kg DPAT (sal–DPAT0.3), saline and 1 mg/kg DPAT (sal–DPAT1), or WAY100635 3 mg/kg–1 mg/kg DPAT (WAY3–DPAT1). sal–DPAT treatments reversed PPI deficits in DAT KO mice (sal–sal group) at pp6 dB and pp12 dB. The ameliorating action of DPAT was antagonized by pretreatment with 3 mg/kg of WAY100635. %PPI values represent mean ± SEM. ***p < 0.001 compared with WT sal–sal; **p < 0.005 compared with WT WAY3–DPAT1; #p < 0.05 compared with DAT KO sal–sal pp6 dB; ##p < 0.001 compared with DAT KO sal–sal pp12 dB; $p < 0.005 compared with DAT KO sal–DPAT1 + WAY3–DPAT1 group. N = 10–14 per treatment condition per genotype (male N = 5–8, female N = 5–7).